SCHEMBL20575703

SCHEMBL20575703

COc1ccc(-c2cc(N)[nH]n2)cc1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 4/20 0.60
PDE4B Q07343 4/20 0.60
PDE4C Q08493 4/20 0.60
PDE4D Q08499 4/20 0.60
MAPT P10636 6/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
GAA P10253 1/20 0.59
KDM4E B2RXH2 4/20 0.56
HSD17B10 Q99714 1/20 0.56
ALDH1A1 P00352 2/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
MAPK1 P28482 3/20 0.55
ALOX15 P16050 2/20 0.55
POLB P06746 1/20 0.55
ALOX12 P18054 1/20 0.55
NFKB1 P19838 1/20 0.55
NFKB2 Q00653 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14910704 0.87 PDE4D (0.67) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL10238578 0.86 MAPT (0.46) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL2056467 0.86 SMN1; SMN2 (0.57) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL14911037 0.86 HDAC3 (0.52) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL10200469 0.86 MAPT (0.46) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL2090174 0.83 MAPT (0.47) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL1662318 0.81 MAPT (0.68) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL27776660 0.80 PDE4A (0.60) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL167088 0.79 MAPT (0.67) MAPTMEN1KMT2AGAAKDM4E
SCHEMBL14910131 0.78 NPC1 (0.51) MAPTMEN1KMT2AGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738033-B2 Trk inhibition NANTBIO, INC. (US) 2020-08-11 US disclosed
US-20180346451-A1 TRK INHIBITION NANTBIO, INC. 2018-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180346451-A1 TRK INHIBITION NGFR, NGF, NTRK1 PDE4A 3083/4885PDE4B 3395/4885PDE4C 3405/4885
US-10738033-B2 Trk inhibition NGF, NGFR, NTRK2 PDE4A 2858/4885PDE4B 2875/4885PDE4C 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.